These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 36308924

  • 41. Development and use of specific ELISA methods for quantifying the biological activity of bevacizumab, cetuximab and trastuzumab in stability studies.
    Suárez I, Salmerón-García A, Cabeza J, Capitán-Vallvey LF, Navas N.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct 01; 1032():155-164. PubMed ID: 27296731
    [Abstract] [Full Text] [Related]

  • 42. Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer.
    Li CSW, Sweeney K, Cronenberger C.
    Cancer Chemother Pharmacol; 2020 Mar 01; 85(3):487-499. PubMed ID: 31768697
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Aggregation of biopharmaceuticals in human plasma and human serum: implications for drug research and development.
    Arvinte T, Palais C, Green-Trexler E, Gregory S, Mach H, Narasimhan C, Shameem M.
    MAbs; 2013 Mar 01; 5(3):491-500. PubMed ID: 23571158
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: Feasibility assessment for future mass spectrometry hyphenation.
    Goyon A, D'Atri V, Colas O, Fekete S, Beck A, Guillarme D.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Oct 15; 1065-1066():35-43. PubMed ID: 28946123
    [Abstract] [Full Text] [Related]

  • 47. Defining the right diluent for intravenous infusion of therapeutic antibodies.
    Luo S, McSweeney KM, Wang T, Bacot SM, Feldman GM, Zhang B.
    MAbs; 2020 Oct 15; 12(1):1685814. PubMed ID: 31774346
    [Abstract] [Full Text] [Related]

  • 48. A Novel Online Four-Dimensional SEC×SEC-IM×MS Methodology for Characterization of Monoclonal Antibody Size Variants.
    Ehkirch A, Goyon A, Hernandez-Alba O, Rouviere F, D'Atri V, Dreyfus C, Haeuw JF, Diemer H, Beck A, Heinisch S, Guillarme D, Cianferani S.
    Anal Chem; 2018 Dec 04; 90(23):13929-13937. PubMed ID: 30371058
    [Abstract] [Full Text] [Related]

  • 49. Qualification of a LC-HRMS platform method for biosimilar development using NISTmab as a model.
    Tank P, Vora S, Tripathi S, D'Souza F.
    Anal Biochem; 2024 May 04; 688():115475. PubMed ID: 38336012
    [Abstract] [Full Text] [Related]

  • 50. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept.
    Cho IH, Lee N, Song D, Jung SY, Bou-Assaf G, Sosic Z, Zhang W, Lyubarskaya Y.
    MAbs; 2016 May 04; 8(6):1136-55. PubMed ID: 27246928
    [Abstract] [Full Text] [Related]

  • 51. Effect of protein cryoconcentration and processing conditions on kinetics of dimer formation for a monoclonal antibody: A case study on bioprocessing.
    Mehta SB, Subramanian S, D'Mello R, Brisbane C, Roy S.
    Biotechnol Prog; 2019 Jul 04; 35(4):e2836. PubMed ID: 31063635
    [Abstract] [Full Text] [Related]

  • 52. Structural and Functional Analysis of CEX Fractions Collected from a Novel Avastin® Biosimilar Candidate and Its Innovator: A Comparative Study.
    Gurel B, Berksoz M, Capkin E, Parlar A, Pala MC, Ozkan A, Capan Y, Daglikoca DE, Yuce M.
    Pharmaceutics; 2022 Jul 28; 14(8):. PubMed ID: 36015197
    [Abstract] [Full Text] [Related]

  • 53. Development of an analytical method for the determination of pimavanserin and its impurities applying analytical quality by design principles as a risk-based strategy.
    Radić I, Runje M, Babić S.
    J Pharm Biomed Anal; 2021 Jul 15; 201():114091. PubMed ID: 33964725
    [Abstract] [Full Text] [Related]

  • 54. Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity.
    Gabrielson JP, Brader ML, Pekar AH, Mathis KB, Winter G, Carpenter JF, Randolph TW.
    J Pharm Sci; 2007 Feb 15; 96(2):268-79. PubMed ID: 17080424
    [Abstract] [Full Text] [Related]

  • 55. A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab.
    Hummel M, Bosje T, Shaw A, Liu MS, Barve A, Kothekar M, Socinski MA, Waller CF.
    J Cancer Res Clin Oncol; 2022 Feb 15; 148(2):487-496. PubMed ID: 33866430
    [Abstract] [Full Text] [Related]

  • 56. A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects.
    Hettema W, Wynne C, Lang B, Altendorfer M, Czeloth N, Lohmann R, Athalye S, Schliephake D.
    Expert Opin Investig Drugs; 2017 Aug 15; 26(8):889-896. PubMed ID: 28651442
    [Abstract] [Full Text] [Related]

  • 57. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.
    Ishii-Watabe A, Kuwabara T.
    Drug Metab Pharmacokinet; 2019 Feb 15; 34(1):64-70. PubMed ID: 30600193
    [Abstract] [Full Text] [Related]

  • 58. An injectable thermosensitive polymeric hydrogel for sustained release of Avastin® to treat posterior segment disease.
    Xie B, Jin L, Luo Z, Yu J, Shi S, Zhang Z, Shen M, Chen H, Li X, Song Z.
    Int J Pharm; 2015 Jul 25; 490(1-2):375-83. PubMed ID: 26027491
    [Abstract] [Full Text] [Related]

  • 59. Proteins from Avastin® (bevacizumab) show tyrosine nitrations for which the consequences are completely unclear.
    Wan J, Csaszar E, Chen WQ, Li K, Lubec G.
    PLoS One; 2012 Jul 25; 7(4):e34511. PubMed ID: 22523550
    [Abstract] [Full Text] [Related]

  • 60. Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.
    Sorensen M, Harmes DC, Stoll DR, Staples GO, Fekete S, Guillarme D, Beck A.
    MAbs; 2016 Oct 25; 8(7):1224-1234. PubMed ID: 27362833
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.